The new guideline for evaluating effects of psychotropic drugs on the performance to drive a motor vehicle in Japan: Comparison with US FDA guideline
Neuropsychopharmacology Reports · 2023
DOI: 10.1002/npr2.12339 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuropsychopharmacology Reports, 2023. Verfasst von Kunihiro Iwamoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya, Japan. Hauptthemen laut MEDLINE: Psychotropic Drugs, Motor Vehicles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
In December 2022, the new guideline for evaluating the effect of psychotropic drugs on the performance to drive a motor vehicle was issued by the Ministry of Health, Labour and Welfare (MHLW) and implemented in Japan. Of the safety information, information on the influence of medications on driving performance is particularly important because it can be relevant to the social functioning of patients. In principle, the package inserts of medications are designed based on evidence and provide precautions regarding the operation of heavy machinery such as automobiles in Japan, the United States, and Europe. The effects of medications on driving performance are generally evaluated in a tiered approach involving nonclinical and clinical studies. Because of the wide variety of functional domains involved in automobile driving, the selection of evaluation methods for a given medication depends on their characteristics, which is a complicated method. Therefore, to evaluate the effects of psychotropic drugs on driving performance efficiently and appropriately, we developed the MHLW guideline that specifically defines the evaluation methods used in pharmacological studies, the neuropsychological tests used in pharmacodynamic studies, and the situations in which driving studies are necessary. Regarding the planning of appropriate drug development strategies, we review the background of the MHLW guideline and its differences from the US Food and Drug Administration (FDA) guideline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
- Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
- Department of Psychiatry, University of Occupational and Environmental Health, Fukuoka, Japan.
- Department of Neuropsychiatry, Aichi Medical University, Nagakute, Japan.
- Institute of Innovation for Future Society, Nagoya University, Nagoya, Japan.
- Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
ORCID-Profile: Kunihiro Iwamoto
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Iwamoto, K., Nakabayashi, T., Yamaguchi, A., Konishi, Y., Saji, M., Yoshimura, R., Kanemoto, K., Aoki, H., Ando, M., & Ozaki, N. (2023). The new guideline for evaluating effects of psychotropic drugs on the performance to drive a motor vehicle in Japan: Comparison with US FDA guideline. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12339
Vancouver
Iwamoto K, Nakabayashi T, Yamaguchi A, Konishi Y, Saji M, Yoshimura R, et al. The new guideline for evaluating effects of psychotropic drugs on the performance to drive a motor vehicle in Japan: Comparison with US FDA guideline. Neuropsychopharmacology Reports. 2023. doi:10.1002/npr2.12339
BibTeX
@article{Iwamoto2023,
author = {Iwamoto, Kunihiro and Nakabayashi, Tetsuo and Yamaguchi, Akiko and Konishi, Yuki and Saji, Momoe and Yoshimura, Reiji and Kanemoto, Kousuke and Aoki, Hirofumi and Ando, Masahiko and Ozaki, Norio},
title = {The new guideline for evaluating effects of psychotropic drugs on the performance to drive a motor vehicle in Japan: Comparison with US FDA guideline},
journal = {Neuropsychopharmacology Reports},
year = {2023},
doi = {10.1002/npr2.12339}
}
EUVIMED